Allogeneic Adipose-Derived Mesenchymal Stem Cells
Erectile Dysfunction
Explore 20 assets in Erectile Dysfunction →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
The Methodist Hospital Research Institute
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07048314CT.gov Stem Cells for Erectile Dysfunction Post RALP | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Erectile Dysfunction
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allogeneic Adipose-Derived Mesenchymal Stem Cells (this asset) | The Methodist Hospital Research Institute | P1/2 | CC · 45 |
| Tadalafil | Surgical Outcomes Research Centre (SOuRCe) | P4 | BB |
| Sildenafil | The Netherlands Cancer Institute | P4 | BB |
| Indocyanine Green | Ankara University | P4 | BB |
| BAY38-9456 | Bayer | P4 | BB |
| Ningmitai | Xintian Pharmaceutical | P4 | BB |
| Vardenafil | Medical University of Vienna | P4 | BB |
| Testosterone Undecylate | University of Roma La Sapienza | P4 | BB |
| Testosterone Enantate | Tulane University | P4 | B |
+30 more in the Erectile Dysfunction cohort
Other indications for Allogeneic Adipose-Derived Mesenchymal Stem Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ulcer Of Lower Limbs | — | P2 | B · 63 |
| Parkinson Disease | — | P2 | CCC · 51 |
| Multiple Sclerosis | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allogeneic Adipose-Derived Mesenchymal Stem Cells in Erectile Dysfunction. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allogeneic-adipose-derived-mesenchymal-stem-cells-erectile-dysfunction
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →